EGFR and chordoma: He was ultimately switched to afatinib and has since demonstrated relatively stable disease for two years, highlighting the potential of this epidermal growth factor receptor (EGFR) inhibitor as a promising targeted therapy in the context of limited systemic treatment options for chordomas.